| |||
March 19, 2019 Divestments will play a vital part in rebalancing life sciences’ portfolios Life sciences companies continue to move toward an interconnected business model focused on patients, and driven by convergence and new technology. Divestments, whether to raise funds for investment in growth areas or to swap assets, are at the heart of these efforts to reshape and reinvigorate the sector. | |||
|